FR14C0060I2 - Derives de quinoleine et leur utilisation en tant qu'inhibiteurs mycobacteriens - Google Patents

Derives de quinoleine et leur utilisation en tant qu'inhibiteurs mycobacteriens

Info

Publication number
FR14C0060I2
FR14C0060I2 FR14C0060C FR14C0060C FR14C0060I2 FR 14C0060 I2 FR14C0060 I2 FR 14C0060I2 FR 14C0060 C FR14C0060 C FR 14C0060C FR 14C0060 C FR14C0060 C FR 14C0060C FR 14C0060 I2 FR14C0060 I2 FR 14C0060I2
Authority
FR
France
Prior art keywords
quinoline derivatives
mycobacterial inhibitors
mycobacterial
inhibitors
quinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR14C0060C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31188461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR14C0060(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of FR14C0060I1 publication Critical patent/FR14C0060I1/fr
Application granted granted Critical
Publication of FR14C0060I2 publication Critical patent/FR14C0060I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
FR14C0060C 2002-07-25 2014-08-18 Derives de quinoleine et leur utilisation en tant qu'inhibiteurs mycobacteriens Active FR14C0060I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39871102P 2002-07-25 2002-07-25
EP03771115A EP1527050B1 (en) 2002-07-25 2003-07-18 Quinoline derivatives and their use as mycobacterial inhibitors
PCT/EP2003/050322 WO2004011436A1 (en) 2002-07-25 2003-07-18 Quinoline derivatives and their use as mycobacterial inhibitors

Publications (2)

Publication Number Publication Date
FR14C0060I1 FR14C0060I1 (enrdf_load_html_response) 2014-10-10
FR14C0060I2 true FR14C0060I2 (fr) 2015-11-20

Family

ID=31188461

Family Applications (1)

Application Number Title Priority Date Filing Date
FR14C0060C Active FR14C0060I2 (fr) 2002-07-25 2014-08-18 Derives de quinoleine et leur utilisation en tant qu'inhibiteurs mycobacteriens

Country Status (37)

Country Link
US (1) US7498343B2 (enrdf_load_html_response)
EP (2) EP1527050B1 (enrdf_load_html_response)
JP (1) JP4484703B2 (enrdf_load_html_response)
KR (1) KR100733577B1 (enrdf_load_html_response)
CN (2) CN101070304B (enrdf_load_html_response)
AP (1) AP2421A (enrdf_load_html_response)
AR (1) AR040673A1 (enrdf_load_html_response)
AT (1) ATE463482T1 (enrdf_load_html_response)
AU (1) AU2003262529B2 (enrdf_load_html_response)
BE (1) BE2014C051I2 (enrdf_load_html_response)
BR (1) BRPI0312927B8 (enrdf_load_html_response)
CA (1) CA2493225C (enrdf_load_html_response)
CY (3) CY1111882T1 (enrdf_load_html_response)
DE (1) DE60332023D1 (enrdf_load_html_response)
DK (2) DK2301544T3 (enrdf_load_html_response)
EA (1) EA008937B1 (enrdf_load_html_response)
ES (2) ES2343458T3 (enrdf_load_html_response)
FR (1) FR14C0060I2 (enrdf_load_html_response)
HR (2) HRP20050045B1 (enrdf_load_html_response)
HU (1) HUS1400047I1 (enrdf_load_html_response)
IL (2) IL166457A (enrdf_load_html_response)
IS (1) IS2914B (enrdf_load_html_response)
LU (1) LU92520I2 (enrdf_load_html_response)
ME (1) ME00131B (enrdf_load_html_response)
MX (1) MXPA05001052A (enrdf_load_html_response)
MY (1) MY143564A (enrdf_load_html_response)
NL (1) NL300684I2 (enrdf_load_html_response)
NO (2) NO329935B1 (enrdf_load_html_response)
NZ (1) NZ538391A (enrdf_load_html_response)
PL (1) PL222801B1 (enrdf_load_html_response)
PT (2) PT2301544E (enrdf_load_html_response)
RS (1) RS52431B (enrdf_load_html_response)
SI (2) SI2301544T1 (enrdf_load_html_response)
TW (1) TWI323730B (enrdf_load_html_response)
UA (1) UA82198C2 (enrdf_load_html_response)
WO (1) WO2004011436A1 (enrdf_load_html_response)
ZA (1) ZA200500680B (enrdf_load_html_response)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG166019A1 (en) * 2004-01-23 2010-11-29 Janssen Pharmaceutica Nv Quinoline derivatives and use thereof as mycobacterial inhibitors
EP1711492B1 (en) 2004-01-23 2008-04-16 Janssen Pharmaceutica N.V. Substituted quinolines and their use as mycobacterial inhibitors
ATE395336T1 (de) * 2004-01-29 2008-05-15 Janssen Pharmaceutica Nv Chinolinderivate zur verwendung als inhibitoren von mycobakterien
JP5081617B2 (ja) * 2004-05-28 2012-11-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 薬剤耐性マイコバクテリア性疾患の処置のための置換キノリン誘導体の使用
PL1797115T3 (pl) * 2004-09-28 2017-12-29 Janssen Pharmaceutica N.V. Domena wiążąca bakteryjnej syntazy ATP
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
JP2006182755A (ja) * 2004-12-24 2006-07-13 Janssen Pharmaceut Nv 潜伏性結核の処置
ES2383908T3 (es) * 2005-05-25 2012-06-27 Janssen Pharmaceutica Nv Proceso para preparar (alfa S, beta R)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol
TWI380819B (zh) * 2005-06-08 2013-01-01 Janssen Pharmaceutica Nv 用作抗細菌劑之喹啉衍生物
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
KR101318181B1 (ko) * 2005-06-09 2013-10-16 얀센 파마슈티카 엔.브이. 항균제로서의 퀴놀린 유도체
JP5349730B2 (ja) * 2005-06-09 2013-11-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗バクテリア剤としてのキノリン誘導体
EA010601B1 (ru) * 2005-06-09 2008-10-30 Янссен Фармацевтика Н.В. Производные хинолина в качестве антибактериальных агентов
RS55601B1 (sr) * 2005-06-28 2017-06-30 Janssen Pharmaceutica Nv Derivati kvinolina kao antibakterijski agensi
JO3270B1 (ar) * 2005-06-28 2018-09-16 Janssen Pharmaceutica Nv مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
JO2752B1 (en) * 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO3077B1 (ar) * 2005-07-28 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينولين مضادة للبكتيريا
JO2952B1 (en) 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2837B1 (en) * 2005-08-03 2014-09-15 جانسن فارمسيتكا ان في Quinoline derivatives acting as antibacterial agents
JO2855B1 (en) * 2005-08-03 2015-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
US8686002B2 (en) 2005-08-21 2014-04-01 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as binding partners for 5-HT5 receptors
DE102005044817A1 (de) 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2685B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO2684B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO2970B1 (en) * 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2725B1 (en) * 2006-12-06 2013-09-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
RU2404971C2 (ru) * 2008-12-02 2010-11-27 ЗАО "Фарм-Синтез" Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе
CN102249935B (zh) * 2010-05-17 2015-05-20 中国人民解放军军事医学科学院毒物药物研究所 芳香2-丁醇类化合物及其医药用途
RU2486175C2 (ru) * 2011-09-12 2013-06-27 Закрытое Акционерное Общество "Фарм-Синтез" Производные хинолина, в частности 5,6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ получения и применение соединений
EA035443B1 (ru) 2012-04-27 2020-06-17 Янссен Фармацевтика Нв Антибактериальные хинолиновые производные
ES2607879T3 (es) 2012-04-27 2017-04-04 Janssen Pharmaceutica N.V. Derivados de quinolina antibacterianos
WO2014014845A1 (en) 2012-07-18 2014-01-23 Vertex Pharmaceuticals Incorporated Combination therapy comprising|1 -ethyl-3-[5-[2-{1 -hydroxy-1 -methyl-ethyl}pyrimidin-5-yl]-7-(tetra hydrofuran-2-|yl}-1 h-benzimidazol-2-yl]urea and derivatives thereof to treat mycobacterium|diseases
CA2892899C (en) 2012-12-21 2021-07-20 Janssen Sciences Ireland Uc Antibacterial compounds
RU2530493C1 (ru) * 2013-04-22 2014-10-10 Закрытое Акционерное Общество "Фарм-Синтез" Производные хинолина, в частности 6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ их получения и применение соединений для лечения инфекционных заболеваний микобактериальной природы, в частности туберкулеза
CN105017147B (zh) * 2014-04-30 2019-02-01 中国医学科学院药物研究所 一种回收和利用Bedaquiline立体化学异构体的方法
CN105085396B (zh) * 2014-05-07 2017-08-08 国药集团国瑞药业有限公司 用于制备贝达喹啉的中间体及其制备方法和应用
CN105085395B (zh) * 2014-05-07 2017-09-26 国药集团国瑞药业有限公司 贝达喹啉的制备方法
CN105198808B (zh) * 2014-05-27 2017-08-25 北京万生药业有限责任公司 一种高效生产贝达喹啉的方法
CN105175329B (zh) * 2014-06-10 2017-09-19 重庆圣华曦药业股份有限公司 一种贝达喹啉消旋体的合成路线及方法
WO2016008381A1 (zh) * 2014-07-14 2016-01-21 辰欣药业股份有限公司 吡啶衍生物及其作为抗分支杆菌的应用
CN105330595B (zh) * 2014-07-14 2019-12-10 上海嘉坦医药科技有限公司 吡啶衍生物及其作为抗分支杆菌的应用
CN105440051B (zh) * 2014-09-19 2019-07-05 重庆医药工业研究院有限责任公司 一种抗结核的噻吩吡啶衍生物
CZ2014708A3 (cs) 2014-10-16 2016-04-27 Zentiva, K.S. Soli Bedaquilinu
CZ201534A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Nové možnosti chirální resoluce bedaquilinu
CZ201535A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Nové možnosti chirální resoluce bedaquilinu
CZ201533A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Způsob izolace směsi enantiomerů
SG11201705944TA (en) 2015-01-27 2017-08-30 Janssen Pharmaceutica Nv Dispersible compositions
WO2016174673A1 (en) * 2015-04-29 2016-11-03 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Anti-phytopathogenic compositions
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs) 2015-06-09 2016-12-21 Zentiva, K.S. Sůl bedaquilinu s kyselinou citronovou
CN113980015A (zh) 2015-07-02 2022-01-28 爱尔兰詹森科学公司 抗细菌化合物
CN105061387A (zh) * 2015-07-17 2015-11-18 苏州大学 二芳基醚类稠环类化合物、制备方法和用途
WO2017015793A1 (zh) * 2015-07-24 2017-02-02 浙江海正药业股份有限公司 一种分离贝达喹啉非对映异构体a的方法
WO2017066926A1 (zh) * 2015-10-20 2017-04-27 浙江海正药业股份有限公司 富马酸贝达喹啉的晶型及其制备方法
CN108473428B (zh) * 2016-01-13 2021-07-23 上海嘉坦医药科技有限公司 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
CN108699047B (zh) * 2016-03-03 2022-03-11 科学与工业研究委员会 作为抗分枝杆菌药剂的取代的橙酮生物碱
WO2017155909A1 (en) * 2016-03-07 2017-09-14 The Global Alliance For Tb Drug Development, Inc. Antibacterial compounds and uses thereof
CA3025727A1 (en) 2016-06-16 2017-12-21 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
KR20190017948A (ko) 2016-06-16 2019-02-20 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 항균제로서의 헤테로고리 화합물
JP7307682B2 (ja) 2017-03-01 2023-07-12 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 併用療法
FI3943070T3 (fi) 2017-07-14 2024-01-24 Janssen Pharmaceutica Nv Pitkävaikutteisia bedakiliiniformulaatioita
CN109384716B (zh) * 2017-08-11 2021-06-29 海创药业股份有限公司 一种氘代喹啉化合物及其制备和用途
KR20210113628A (ko) 2019-01-09 2021-09-16 얀센 파마슈티카 엔.브이. 비결핵성 마이코박테리아 질환의 치료에서의 조합물
WO2020161743A1 (en) 2019-02-08 2020-08-13 Mylan Laboratories Limited Process for the preparation of bedaquiline fumarate
AU2020346370A1 (en) 2019-09-13 2022-05-05 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2021057190A1 (zh) * 2019-09-29 2021-04-01 上海阳帆医药科技有限公司 喹啉类化合物、其制备方法和用途
US20220372033A1 (en) 2019-09-30 2022-11-24 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
AU2020358643A1 (en) 2019-09-30 2022-05-26 Janssen Sciences Ireland Unlimited Company 4-quinolinone antibacterial compounds
CN110804016B (zh) * 2019-12-05 2022-11-04 福建省微生物研究所 抗结核分枝杆菌的二芳基喹啉衍生物
AU2020414492A1 (en) 2019-12-27 2022-08-18 TECNIMEDE - Sociedade Técnico-medicinal, SA Antibacterial quinolines
KR102303635B1 (ko) 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
CA3182425A1 (en) 2020-07-09 2022-01-13 Rene Holm Long-acting formulations
CA3182854A1 (en) 2020-07-09 2022-01-13 Rene Holm Long-acting formulations
WO2022008644A1 (en) 2020-07-09 2022-01-13 Janssen Pharmaceutica Nv Long-acting formulations
US20230346770A1 (en) 2020-11-12 2023-11-02 Janssen Pharmaceutica Nv Combination of bedaquiline, ethambutol and a macrolide in the treatment of nontuberculous mycobacterial diseases
KR20230157400A (ko) 2021-03-16 2023-11-16 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 항박테리아성 화합물
CN117440958A (zh) 2021-03-17 2024-01-23 爱尔兰詹森科学公司 抗菌化合物
JP2024509997A (ja) 2021-03-17 2024-03-05 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 抗菌化合物
WO2022214520A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2022214519A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
US20240279217A1 (en) 2021-06-29 2024-08-22 TECNIMEDE - Sociedade Técnico-medicinal, SA Heterocyclic compounds for the treatment of tuberculosis
KR20240090864A (ko) 2021-10-28 2024-06-21 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 세균성 감염의 치료에 사용하기 위한 이미다조피리딘 아미드 및 관련 화합물
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
CN114835641B (zh) * 2022-05-07 2024-03-15 南京杰运医药科技有限公司 一种3-苄基-6-溴-2-甲氧基喹啉的合成方法
CN117050006A (zh) * 2022-05-13 2023-11-14 广州嘉越医药科技有限公司 一种吡啶衍生物、中间体、制备方法和应用
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
CN119968203A (zh) 2022-09-28 2025-05-09 詹森药业有限公司 长效配制品
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
KR20250083557A (ko) 2022-11-15 2025-06-10 일라이 릴리 앤드 캄파니 Ahr 효능제
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
WO2025068448A1 (en) 2023-09-28 2025-04-03 Janssen Pharmaceutica Nv Atp synthase inhibitors for use in the treatment of non-tuberculosis mycobacteria
WO2025181475A1 (en) 2024-02-27 2025-09-04 The University Of Liverpool Novel tuberculosis sterilization formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0936866A4 (en) * 1996-10-28 2001-04-11 Dept Of The Army Us Government Compounds, compositions and methods for treating antibiotic-resistant infections
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
EP0991623A2 (en) * 1997-06-19 2000-04-12 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
AU6645198A (en) * 1998-01-23 1999-08-09 Fire Armour Pte Ltd Nozzle with axially and perpendicularly directed apertures
JP2002501061A (ja) * 1998-01-26 2002-01-15 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 抗菌剤用キノリン誘導体
US6819431B2 (en) * 2001-07-06 2004-11-16 Zygo Corporation Polymer retarder
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents

Also Published As

Publication number Publication date
EP2301544B1 (en) 2012-09-19
AU2003262529A1 (en) 2004-02-16
IL202655A (en) 2012-04-30
DK2301544T3 (da) 2013-01-02
NL300684I2 (enrdf_load_html_response) 2016-10-11
IL166457A0 (en) 2006-01-15
CA2493225A1 (en) 2004-02-05
EA008937B1 (ru) 2007-10-26
ES2395237T3 (es) 2013-02-11
CN1671667A (zh) 2005-09-21
ZA200500680B (en) 2006-08-30
AR040673A1 (es) 2005-04-13
CN101070304B (zh) 2011-10-26
MY143564A (en) 2011-05-31
LU92520I2 (fr) 2015-11-02
BE2014C051I2 (enrdf_load_html_response) 2022-08-09
HUS1400047I1 (hu) 2016-09-28
ES2343458T3 (es) 2010-08-02
NO329935B1 (no) 2011-01-24
TW200410939A (en) 2004-07-01
FR14C0060I1 (enrdf_load_html_response) 2014-10-10
NO20050476L (no) 2005-01-27
HRP20050045B1 (hr) 2013-09-30
AU2003262529B2 (en) 2009-11-19
NO2014021I2 (enrdf_load_html_response) 2014-08-20
MEP9208A (en) 2010-06-10
BRPI0312927B8 (pt) 2021-05-25
ME00131B (me) 2010-10-10
HRP20050045A2 (en) 2006-06-30
NZ538391A (en) 2005-10-28
HRP20120190A2 (hr) 2012-05-31
IS2914B (is) 2014-12-15
AP2005003210A0 (en) 2005-03-31
PT1527050E (pt) 2010-06-22
EP1527050B1 (en) 2010-04-07
PT2301544E (pt) 2012-12-10
CY2014033I1 (el) 2016-04-13
EP1527050A1 (en) 2005-05-04
EP2301544A1 (en) 2011-03-30
CY1111882T1 (el) 2015-11-04
CY2014033I2 (el) 2016-04-13
IS7620A (is) 2004-12-29
HK1113795A1 (en) 2008-10-17
PL375523A1 (en) 2005-11-28
SI1527050T1 (sl) 2010-08-31
BRPI0312927B1 (pt) 2018-07-10
DE60332023D1 (de) 2010-05-20
RS20050058A (en) 2007-06-04
TWI323730B (en) 2010-04-21
UA82198C2 (uk) 2008-03-25
HRP20120190B1 (hr) 2017-06-02
PL222801B1 (pl) 2016-09-30
NO2014021I1 (no) 2014-08-20
DK1527050T3 (da) 2010-07-19
KR100733577B1 (ko) 2007-06-29
US20050148581A1 (en) 2005-07-07
WO2004011436A1 (en) 2004-02-05
SI2301544T1 (sl) 2013-01-31
HK1083496A1 (en) 2006-07-07
JP4484703B2 (ja) 2010-06-16
RS52431B (en) 2013-02-28
CN1325475C (zh) 2007-07-11
JP2006504658A (ja) 2006-02-09
BR0312927A (pt) 2005-07-12
US7498343B2 (en) 2009-03-03
CA2493225C (en) 2012-03-20
IL166457A (en) 2011-10-31
MXPA05001052A (es) 2005-04-08
EA200500257A1 (ru) 2005-06-30
CY1113497T1 (el) 2016-06-22
CN101070304A (zh) 2007-11-14
ATE463482T1 (de) 2010-04-15
AP2421A (en) 2012-06-08
HRP20120190A8 (hr) 2012-07-31
KR20050033607A (ko) 2005-04-12

Similar Documents

Publication Publication Date Title
FR14C0060I2 (fr) Derives de quinoleine et leur utilisation en tant qu'inhibiteurs mycobacteriens
FR18C1024I2 (fr) Derives d'heterocyclocarboxamide
CY2012026I1 (el) Παραγωγα κουιναζολινης ως αναστολεις vegf
FR15C0086I2 (fr) Derives d'hydroxamate en tant qu'inhibiteurs de desacetylase
ATE428423T1 (de) Aripiprazol-komplex-formulierung und verfahren
NO20032909D0 (no) Glukopyranosyloksypyrazolderivater samt medikamentell anvendelse derav
ATE253576T1 (de) 8-chinolinxanthin and 8-isochinolinxanthin derivate als pde 5 inhibitoren
EE200300325A (et) Asendatud amiini derivaadid ning nende kasutamismeetodid
EP1504429A4 (en) MONITORING SYSTEM AND ASSOCIATED METHOD
EP1512396A4 (en) HEMMER AGAINST ACTIVATION OF AP-1 AND NFAT
ATE266023T1 (de) Amid-derivate
NO20031097D0 (no) Kinolinderivater
AR028253A1 (es) Inhibidores de la glucogeno fosforilasa
DE60015089D1 (de) 3-phenylpyridinderivative und deren verwendung als nk-1 rezeptorantagonisten
NO20020526D0 (no) Moksifloksasinformulering med koksalt
EE200400042A (et) 8/17 heterotsüklilised ühendid ning nende kasutamine D-alanüül-D-alaniini ligaasi inhibiitoritena
NO20023013L (no) Substituerte 8-arylkinolin-fosfodiesterase-4-inhibitorer
NO20032807D0 (no) Substituerte 8-arylkinolin-fosfodiesterase-4-inhibitorer
EE200100371A (et) Amidinobensüülamiini derivaadid ja nende kasutamine trombiini inhibiitoritena
ITRM20020306A0 (it) Esteri in posizione 20 di camptotecine.
DE60311233D1 (de) Chinolinderivate
EP1677734A4 (en) CYSTATIN-C AS ANTAGONIST OF TGF-B AND RELEVANT PROCEDURE
ATE367379T1 (de) Quinolin-derivate als antientzündungsmittel
SE514398E (sv) Förfarande vid spetsdragning
ITMI20020158A1 (it) Procedimento atto all'individuazione di incendi